Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

International Conference on Advanced Computer Information Technologies (ACIT)

Quantum Value Equation: A Minimal Decision Model for Quantum-Assisted Oncology Drug Discovery Assessment

Bartosz Szczęsny, Wiesława Gryncewicz

Published Sep 1, 2026• 0 citations
Publisher
DOI
10.1109/acit69831.2026.11700173

Related papers

Quantum-Assisted Drug Discovery for Lung Cancer

Kaushalya Thopate, Nandini Naik, Ayushi Patil +2 more

International Conference on Trends in Quantum Computing and Emerging Business Technologies (TQCEBT)•Apr 1, 2026•0 citations

The Rise of Generalist Foundation Models and Quantum Computing in Oncology

Manish Kakar

In the field of oncology, Artificial intelligence (AI) and deep learning (DL) are an essential component of decision-support. However, traditional narrow-AI models have significant limitations in clinics with respect to narrow, task-specificity (TS), high data requirement and interpretability. Moreover, the absence of common clinical criteria and the lack of doctors in the co-development of explainable AI (XAI) have undermined the implementation causing conflict with general data protection regulation (GDPR), trust and ethical integration requirements. The application of AI/DL tools in clinics are often constrained by TS, heavy dependency on hyperparameter tuning and large data volume. This review fills in these gaps by creating a cohesive framework that links problem-driven clinical demands with emerging technologies, specifically, the convergence of Generalist Medical AI (GMAI) and Quantum Oncology (QO). Although GMAI's use foundation models, have high computational requirements and have inherent complexity in their validation pipelines, they are designed to be based on self-supervised learning from multimodal data to address a range of downstream clinical tasks. This review aims to critically discuss the potential of quantum computing (QC) to augment GMAI for more efficient data processing, medical imaging, drug discovery, and genomic analysis, owing to the inherent strengths of quantum superposition and entanglement that surpass the capabilities of classical AI/DL systems. Structural and technical trade-offs of this paradigm change are also discussed. We also give recommendations for safe bedside translation by facilitating a common assessment through clinician in the loop design, the CLAIM checklist, and the framework FUTURE-AI. Finally, this analysis outlines oncology and quantum convergence into quantum oncology (QO). This enables scalable, sustainable, and precision oncology while respecting ethics and privacy.

Technology in Cancer Research & Treatment•Aug 1, 2026•0 citations

Drug Discovery with Quantum Machine Learning

Alexey Pyrkov, Alex Aliper, Dmitry S. Bezrukov +1 more

Springer eBooks•Jan 1, 2026•0 citations

Quantum-machine-assisted drug discovery

Yidong Zhou, Jintai Chen, Jinglei Cheng +8 more

Drug discovery is lengthy and expensive, with traditional computer-aided design facing limits. This paper examines integrating quantum computing across the drug development cycle to accelerate and enhance workflows and rigorous decision-making. It highlights quantum approaches for molecular simulation, drug-target interaction prediction, and optimizing clinical trials. Leveraging quantum capabilities could accelerate timelines and costs for bringing therapies to market, improving efficiency and ultimately benefiting public health.

arXiv:2408.13479•npj Drug Discovery.•Jan 7, 2026•12 citations

Quantum Assisted Drug Discovery in Human Beings

B S Anupama, Amrit S R, A Chetan Kumar

The large search space and the challenge of accurately simulating quantum-level molecular interactions are the fundamental causes of the delayed, complicated, and costly process of discovering new medications. The effectiveness of conventional computational techniques, including molecular docking and molecular dynamics, to assess molecular characteristics and provide highly accurate drug candidate predictions is constrained. This paper presents a Quantum-Assisted Drug Discovery Simulation framework that combines cutting-edge quantum computing algorithms, specifically the Quantum Approximate Optimization Algorithm (QAOA) and the Variational Quantum Eigensolver (VQE), with traditional molecular docking tools like RDKit and AutoDock. The system uses these quantum algorithms to perform very accurate Quantum Refinement on the most potential therapeutic protein poses found by classical identification. This hybrid approach seeks to optimize drug-protein interactions more quickly, speed up early-stage drug discovery, and create opportunities for less costly, more accurate medical research, even though a combination of quantum and classical calculations allows more accurate prediction of molecular energies and binding affinities.

International Conference on Knowledge Engineering and Communication Systems (ICKECS)•Apr 24, 2026•0 citations

Quantum Computing in Drug Discovery

Nilesh Ingale Nilesh Ingale

INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT•Sep 1, 2026•0 citations
In the field of oncology, Artificial intelligence (AI) and deep learning (DL) are an essential component of decision-support. However, traditional narrow-AI models have significant limitations in clinics with respect to narrow, task-specificity (TS), high data requirement and interpretability. Moreover, the absence of common clinical criteria and the lack of doctors in the co-development of explainable AI (XAI) have undermined the implementation causing conflict with general data protection regulation (GDPR), trust and ethical integration requirements. The application of AI/DL tools in clinics are often constrained by TS, heavy dependency on hyperparameter tuning and large data volume. This review fills in these gaps by creating a cohesive framework that links problem-driven clinical demands with emerging technologies, specifically, the convergence of Generalist Medical AI (GMAI) and Quantum Oncology (QO). Although GMAI's use foundation models, have high computational requirements and have inherent complexity in their validation pipelines, they are designed to be based on self-supervised learning from multimodal data to address a range of downstream clinical tasks. This review aims to critically discuss the potential of quantum computing (QC) to augment GMAI for more efficient data processing, medical imaging, drug discovery, and genomic analysis, owing to the inherent strengths of quantum superposition and entanglement that surpass the capabilities of classical AI/DL systems. Structural and technical trade-offs of this paradigm change are also discussed. We also give recommendations for safe bedside translation by facilitating a common assessment through clinician in the loop design, the CLAIM checklist, and the framework FUTURE-AI. Finally, this analysis outlines oncology and quantum convergence into quantum oncology (QO). This enables scalable, sustainable, and precision oncology while respecting ethics and privacy.
Drug discovery is lengthy and expensive, with traditional computer-aided design facing limits. This paper examines integrating quantum computing across the drug development cycle to accelerate and enhance workflows and rigorous decision-making. It highlights quantum approaches for molecular simulation, drug-target interaction prediction, and optimizing clinical trials. Leveraging quantum capabilities could accelerate timelines and costs for bringing therapies to market, improving efficiency and ultimately benefiting public health.
The large search space and the challenge of accurately simulating quantum-level molecular interactions are the fundamental causes of the delayed, complicated, and costly process of discovering new medications. The effectiveness of conventional computational techniques, including molecular docking and molecular dynamics, to assess molecular characteristics and provide highly accurate drug candidate predictions is constrained. This paper presents a Quantum-Assisted Drug Discovery Simulation framework that combines cutting-edge quantum computing algorithms, specifically the Quantum Approximate Optimization Algorithm (QAOA) and the Variational Quantum Eigensolver (VQE), with traditional molecular docking tools like RDKit and AutoDock. The system uses these quantum algorithms to perform very accurate Quantum Refinement on the most potential therapeutic protein poses found by classical identification. This hybrid approach seeks to optimize drug-protein interactions more quickly, speed up early-stage drug discovery, and create opportunities for less costly, more accurate medical research, even though a combination of quantum and classical calculations allows more accurate prediction of molecular energies and binding affinities.